These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31147489)

  • 21. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
    Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
    BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
    Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
    Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
    Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C
    Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
    Yusof MM; Abdullah NM; Sharial MM; Zaatar A
    Asian Pac J Cancer Prev; 2016; 17(3):973-8. PubMed ID: 27039822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
    Joulain F; Proskorovsky I; Allegra C; Tabernero J; Hoyle M; Iqbal SU; Van Cutsem E
    Br J Cancer; 2013 Oct; 109(7):1735-43. PubMed ID: 24045663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.
    Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS
    Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
    Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
    Kimura M; Usami E; Teramachi H; Yoshimura T
    Anticancer Res; 2021 Jun; 41(6):3091-3097. PubMed ID: 34083302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
    Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
    Riechelmann RP; Srimuninnimit V; Bordonaro R; Kavan P; Di Bartolomeo M; Maiello E; Cicin I; García-Alfonso P; Chau I; Fedyanin MY; Martos CF; Ter-Ovanesov M; Peeters M; Ko YJ; Yalcin S; Karthaus M; Aparicio J; Heinemann V; Picard P; Bury D; Drea E; Sobrero A
    Clin Colorectal Cancer; 2019 Sep; 18(3):183-191.e3. PubMed ID: 31221542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
    André T; Chibaudel B
    Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
    Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
    Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI.
    Catalano M; Lavacchi D; Giommoni E; Shabani S; Guidolin A; Brugia M; Petrioli R; Ramello M; Pillozzi S; Antonuzzo L; Roviello G
    Future Oncol; 2023 Dec; 19(38):2537-2546. PubMed ID: 38050741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.